These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21181124)

  • 1. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.
    Black MD; Stevens RJ; Rogacki N; Featherstone RE; Senyah Y; Giardino O; Borowsky B; Stemmelin J; Cohen C; Pichat P; Arad M; Barak S; De Levie A; Weiner I; Griebel G; Varty GB
    Psychopharmacology (Berl); 2011 May; 215(1):149-63. PubMed ID: 21181124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.
    Liebig M; Gossel M; Pratt J; Black M; Haschke G; Elvert R; Juretschke HP; Neumann-Haefelin C; Kramer W; Herling AW
    Obesity (Silver Spring); 2010 Oct; 18(10):1952-8. PubMed ID: 20168311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.
    Gacsályi I; Nagy K; Pallagi K; Lévay G; Hársing LG; Móricz K; Kertész S; Varga P; Haller J; Gigler G; Szénási G; Barkóczy J; Bíró J; Spedding M; Antoni FA
    Neuropharmacology; 2013 Jan; 64():254-63. PubMed ID: 22824189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625.
    Zuurman L; Roy C; Schoemaker RC; Amatsaleh A; Guimaeres L; Pinquier JL; Cohen AF; van Gerven JM
    J Psychopharmacol; 2010 Mar; 24(3):363-71. PubMed ID: 18801827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats.
    Herling AW; Gossel M; Haschke G; Stengelin S; Kuhlmann J; Müller G; Schmoll D; Kramer W
    Am J Physiol Endocrinol Metab; 2007 Sep; 293(3):E826-32. PubMed ID: 17595216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia.
    Zuckerman L; Rimmerman N; Weiner I
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):298-307. PubMed ID: 12827344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.
    Black MD; Varty GB; Arad M; Barak S; De Levie A; Boulay D; Pichat P; Griebel G; Weiner I
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):385-96. PubMed ID: 18709358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
    Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine.
    Guidali C; Viganò D; Petrosino S; Zamberletti E; Realini N; Binelli G; Rubino T; Di Marzo V; Parolaro D
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):17-28. PubMed ID: 20196921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.
    Weiner I
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):257-97. PubMed ID: 12601500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
    Wadenberg ML; Fjällström AK; Federley M; Persson P; Stenqvist P
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):644-54. PubMed ID: 20701827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychopharmacological study of agmatine in behavioral tests of schizophrenia in rodents.
    Kotagale NR; Taksande BG; Wadhwani PJ; Palhade MW; Mendhi SM; Gawande DY; Hadole PN; Chopde CT
    Pharmacol Biochem Behav; 2012 Jan; 100(3):398-403. PubMed ID: 21989253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2009 Mar; 12(2):227-41. PubMed ID: 18687163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.
    Southam E; Cilia J; Gartlon JE; Woolley ML; Lacroix LP; Jennings CA; Cluderay JE; Reavill C; Rourke C; Wilson DM; Dawson LA; Medhurst AD; Jones DN
    Psychopharmacology (Berl); 2009 Jan; 201(4):483-94. PubMed ID: 18762914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice.
    Lipina TV; Palomo V; Gil C; Martinez A; Roder JC
    Neuropharmacology; 2013 Jan; 64():205-14. PubMed ID: 22749842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.
    Barak S; Arad M; De Levie A; Black MD; Griebel G; Weiner I
    Neuropsychopharmacology; 2009 Jun; 34(7):1753-63. PubMed ID: 19158670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia.
    Nishiyama K; Suzuki H; Harasawa T; Suzuki N; Kurimoto E; Kawai T; Maruyama M; Komatsu H; Sakuma K; Shimizu Y; Shimojo M
    J Pharmacol Exp Ther; 2017 Nov; 363(2):253-264. PubMed ID: 28851764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders.
    Osborne AL; Solowij N; Babic I; Lum JS; Huang XF; Newell KA; Weston-Green K
    Brain Behav Immun; 2019 Oct; 81():574-587. PubMed ID: 31326506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.